Pharmaceutical
Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England
PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals (“GW”; now part of Jazz Pharmaceuticals plc), a world leader in discovering, developing and delivering regulatory approved cannabinoid-based medicines, has been recommended for reimbursement by National Institute for Health and Care Excellence (NICE) for adjunctive therapy…
